- Home
- FULT vs VKTX Comparison
FULT vs VKTX Comparison
Compare FULT & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULT
- VKTX
- Stock Information
- Founded
- FULT 1882
- VKTX 2012
- Country
- FULT United States
- VKTX United States
- Employees
- FULT N/A
- VKTX N/A
- Industry
- FULT Major Banks
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- FULT Finance
- VKTX Health Care
- Exchange
- FULT Nasdaq
- VKTX Nasdaq
- Market Cap
- FULT 3.4B
- VKTX 3.5B
- IPO Year
- FULT N/A
- VKTX 2015
- Fundamental
- Price
- FULT $18.60
- VKTX $34.42
- Analyst Decision
- FULT Hold
- VKTX Strong Buy
- Analyst Count
- FULT 3
- VKTX 13
- Target Price
- FULT $20.67
- VKTX $86.92
- AVG Volume (30 Days)
- FULT 2.0M
- VKTX 4.1M
- Earning Date
- FULT 07-15-2025
- VKTX 07-23-2025
- Dividend Yield
- FULT 3.87%
- VKTX N/A
- EPS Growth
- FULT 2.12
- VKTX N/A
- EPS
- FULT 1.71
- VKTX N/A
- Revenue
- FULT $1,211,863,000.00
- VKTX N/A
- Revenue This Year
- FULT N/A
- VKTX N/A
- Revenue Next Year
- FULT $4.30
- VKTX N/A
- P/E Ratio
- FULT $10.89
- VKTX N/A
- Revenue Growth
- FULT 17.67
- VKTX N/A
- 52 Week Low
- FULT $14.33
- VKTX $18.92
- 52 Week High
- FULT $22.49
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- FULT 47.95
- VKTX 73.08
- Support Level
- FULT $18.35
- VKTX $31.22
- Resistance Level
- FULT $19.99
- VKTX $33.61
- Average True Range (ATR)
- FULT 0.48
- VKTX 1.77
- MACD
- FULT -0.12
- VKTX 0.32
- Stochastic Oscillator
- FULT 15.24
- VKTX 89.49
About FULT Fulton Financial Corporation
Fulton Financial Corp is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.